Genmab

GMAB · Nasdaq · Denmark

Share price · GMAB

$50.97+18.01 (+54.64%) 3M

close as of 2026-11-18 · 24h delayed · vol 3.0M (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when GMAB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 28 Oct 2026+28.3%
  2. 23 Oct 2026+9.5%
  3. 5 Oct 2026+10.7%
  4. 15 Sep 2026+4.6%
  5. 30 Jun 2026+5.6%
  6. 2 Jun 2026-6.3%
  7. 20 May 2026+6.0%
  8. 3 Mar 2026-6.7%
  9. 4 Feb 2026-3.4%
  10. 23 Jan 2026+2.4%

Share of unusual movement by asset

For each asset, the share of GMAB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Amivantamab
events and moves
2433%
Epcoritamab
events and moves
125%
Tisotumab Vedotin Humax-tf-adc (Tivdak)
events and moves
7shown from 8 days
Rinatabart sesutecan (Rina-S)
events and moves
2shown from 8 days
Zenocutuzumab (Bizengri)
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—7%
Other company news (earnings, financing, releases naming no asset)—24%
Sessions with no dated event—30%

Assets

(8 total)
8Total Assets
4Approved
1Phase 3 / Filed
3Phase 1–2 / Early
13Diseases
Quick filter:
Showing 8 of 8 assets
Target & Modality
Approved
EGFR x c-METMultispecific antibody
Non-Small Cell Lung CancerColorectal CancerHead and Neck Squamous Cell Carcinoma
Approved
CD20 x CD3Multispecific antibody
Diffuse Large B-Cell LymphomaFollicular LymphomaNon-Hodgkin Lymphoma
Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma
Approved
Tissue Factor (TF)Antibody–drug conjugate
Non-Small Cell Lung CancerCervical Cancer
Zenocutuzumab(Bizengri)
Approved
HER2; HER3 (blocks NRG1 binding to HER3)Multispecific antibody
Non-Small Cell Lung CancerBiliary Tract CancerPancreatic Ductal Adenocarcinoma
Cholangiocarcinoma
Phase 3
Folate receptor alpha (FRα)Antibody–drug conjugate
Non-Small Cell Lung CancerBreast CancerOvarian CancerEndometrial Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 2
EGFR x c-METMultispecific antibody
Non-Small Cell Lung Cancer
Phase 1/2
CD40 x 4-1BB (dual)Monoclonal antibody
Non-Small Cell Lung Cancer
Phase 1
CD3 x FLT3Biologic (subtype unspecified)
Acute Myeloid Leukemia

Upcoming events

(35 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Zenocutuzumab · BizengriPhase 2Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Est. primary completion 2026-12-31 · NCT02912949 · CT.gov ↗
What to watch
2027 (14)
January 2027 (1)
AmivantamabPhase 1/2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2027-01-31 · NCT05908734 · CT.gov ↗
What to watch
March 2027 (1)
EpcoritamabPhase 2Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma
Est. primary completion 2027-03 · NCT05451810 · CT.gov ↗
What to watch
April 2027 (2)
AmivantamabPhase 1/2Advanced or Metastatic Colorectal Cancer
Est. primary completion 2027-04-27 · NCT05379595 · CT.gov ↗
What to watch
AmivantamabPhase 1/2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2027-04-28 · NCT05488314 · CT.gov ↗
What to watch
May 2027 (1)
AmivantamabPhase 2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2027-05-31 · NCT06120140 · CT.gov ↗
What to watch
June 2027 (1)
EpcoritamabPhase 3Diffuse Large B-Cell Lymphoma
Est. primary completion 2027-06 · NCT05578976 · CT.gov ↗
What to watch
August 2027 (1)
AmivantamabPhase 2Carcinoma, Non-small-Cell Lung
Est. primary completion 2027-08-17 · NCT05498428 · CT.gov ↗
What to watch
September 2027 (3)
EpcoritamabPhase 1/2Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma …
Est. primary completion 2027-09 · NCT04542824 · CT.gov ↗
What to watch
Rinatabart sesutecan (Rina-S)Phase 3Platinum-resistant Ovarian Cancer
Est. primary completion 2027-09 · NCT07604766 · CT.gov ↗
What to watch
EpcoritamabPhase 1/2Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Est. primary completion 2027-09-30 · NCT04663347 · CT.gov ↗
What to watch
October 2027 (1)
EpcoritamabPhase 1/2B-Cell Non-Hodgkin Lymphoma
Est. primary completion 2027-10 · NCT05201248 · CT.gov ↗
What to watch
November 2027 (1)
Rinatabart sesutecan (Rina-S)Phase 2Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2027-11-22 · NCT07288177 · CT.gov ↗
What to watch
December 2027 (2)
EpcoritamabPhase 1/2Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome …
Est. primary completion 2027-12 · NCT04623541 · CT.gov ↗
What to watch
AmivantamabPhase 3Colorectal Neoplasms
Est. primary completion 2027-12-15 · NCT06750094 · CT.gov ↗
What to watch
2028 (9)
March 2028 (2)
EpcoritamabPhase 3Diffuse Large B-Cell Lymphoma
Est. primary completion 2028-03 · NCT06508658 · CT.gov ↗
What to watch
AmivantamabPhase 2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2028-03-02 · NCT07586202 · CT.gov ↗
What to watch
April 2028 (2)
PamvatamigPhase 2Non-Small Cell Lung Cancer
Est. primary completion 2028-04 · NCT06885840 · CT.gov ↗
What to watch
PamvatamigPhase 1/2Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer
Est. primary completion 2028-04-30 · NCT04930432 · CT.gov ↗
What to watch
September 2028 (1)
Rinatabart sesutecan (Rina-S)Phase 2Gastrointestinal Cancers
Est. primary completion 2028-09 · NCT07539311 · CT.gov ↗
What to watch
October 2028 (1)
Rinatabart sesutecan (Rina-S)Phase 3Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC
Est. primary completion 2028-10 · NCT07225270 · CT.gov ↗
What to watch
November 2028 (1)
AmivantamabPhase 1/2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2028-11-30 · NCT07227025 · CT.gov ↗
What to watch
December 2028 (2)
Rinatabart sesutecan (Rina-S)Phase 1/2High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer …
Est. primary completion 2028-12 · NCT05579366 · CT.gov ↗
What to watch
AmivantamabPhase 3Colorectal Neoplasms
Est. primary completion 2028-12-15 · NCT06662786 · CT.gov ↗
What to watch
2029 (7)
January 2029 (1)
EpcoritamabPhase 1/2DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL) …
Est. primary completion 2029-01 · NCT03625037 · CT.gov ↗
What to watch
February 2029 (1)
PamvatamigPhase 1/2Solid Advanced Tumor
Est. primary completion 2029-02-01 · NCT07448116 · CT.gov ↗
What to watch
May 2029 (1)
AmivantamabPhase 2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2029-05-23 · NCT06667076 · CT.gov ↗
What to watch
June 2029 (1)
AmivantamabPhase 3Squamous Cell Carcinoma of Head and Neck
Est. primary completion 2029-06-18 · NCT07276399 · CT.gov ↗
What to watch
August 2029 (1)
Rinatabart sesutecan (Rina-S)Phase 3Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
Est. primary completion 2029-08 · NCT07166094 · CT.gov ↗
What to watch
December 2029 (2)
EpcoritamabPhase 3Follicular Lymphoma (FL)
Est. primary completion 2029-12 · NCT05409066 · CT.gov ↗
What to watch
Rinatabart sesutecan (Rina-S)Phase 3Platinum-Sensitive Ovarian Cancer, Ovarian Cancer
Est. primary completion 2029-12 · NCT07564141 · CT.gov ↗
What to watch
2030 (1)
March 2030 (1)
Rinatabart sesutecan (Rina-S)Phase 3Ovarian Cancer
Est. primary completion 2030-03 · NCT07859215 · CT.gov ↗
What to watch
2032 (2)
November 2032 (1)
EpcoritamabPhase 2Non-Hodgkin Lymphoma
Est. primary completion 2032-11 · NCT05283720 · CT.gov ↗
What to watch
December 2032 (1)
AmivantamabPhase 1/2Squamous Cell Carcinoma of Head and Neck
Est. primary completion 2032-12-27 · NCT06385080 · CT.gov ↗
What to watch
2037 (1)
November 2037 (1)
EpcoritamabPhase 3Follicular Lymphoma (FL)
Est. primary completion 2037-11 · NCT06191744 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(11)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 October 2026Topline resultRina-SPhase 3 RAINFOL-02 (NCT06619236) met PFS and key secondary OS
Genmab · Source ↗
October 2026Topline resultEpcoritamabPhase 3 EPCORE DLBCL-2 positive topline results
July 2026ApprovalEpcoritamabEuropean Commission approves Tepkinly with lenalidomide and rituximab in R/R follicular lymphoma
EU, European Commission · Source ↗
8 June 2026ApprovalTisotumab Vedotin Humax-tf-adcNMPA approves TIVDAK for recurrent or metastatic cervical cancer
CN, NMPA · Source ↗
June 2026Topline resultEpcoritamabPhase 3 EPCORE DLBCL-4 met its progression-free survival primary endpoint
8 May 2026ApprovalZenocutuzumabFDA Boxed Warning on Bizengri (BLA761352)
US, FDA · FDA · Source ↗
23 February 2026ApprovalAmivantamabEC approves subcutaneous amivantamab Q3W and Q4W dosing
EU, EMA · Source ↗
17 February 2026ApprovalAmivantamabFDA approves monthly dosing schedule for RYBREVANT FASPRO
US, FDA · Source ↗
16 January 2026Topline resultEpcoritamabEPCORE DLBCL-1 phase 3 topline
Genmab · Source ↗
18 November 2025ApprovalEpcoritamabFDA approves EPKINLY + R2 for relapsed/refractory follicular lymphoma
US, FDA · Source ↗
1 September 2025ApprovalTisotumab Vedotin Humax-tf-adcTIVDAK approved in Hong Kong
HK, Hong Kong Department of Health · Source ↗

Financial reports

Quarterly & interim (4)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3——$1.8B—report ↗

For the third quarter of 2025, Genmab did not disclose revenue, R&D spend, or net income/loss in the provided material. The company reported cash and equivalents of $1,761M, with no quarterly net burn figure provided.

Genmab announced it will discontinue clinical development of acasunlimab following a portfolio review, prioritizing late-stage programs including EPKINLY (epcoritamab), petosemtamab, and rinatabart sesutecan (Rina-S). The company stated that this decision does not impact its full year 2025 financial guidance.

View 3 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-Q2$780M$361M$622M—report ↗
2023-Q2$614M$271M$1.6B—report ↗
2022-Q2$453M$183M$1.4B—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$3.7B———report ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$3.1B$1.4B$1.4B—$1.1B operating cash flowreport ↗
2023-FY$2.4B$1.1B$2.2B—$1.1B operating cash flowreport ↗
2022-FY$2.1B$788M$1.4B—$554M operating cash flowreport ↗
2021-FY$1.3B$665M$1.4B—$354M operating cash flowreport ↗

Insider transactions

This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 270 reporting institutions held 81.9M shares ($2.2B, 13.1% of shares outstanding).

#InstitutionSharesValue
1Orbis Allan Gray Ltd12,925,578$346.8M
2ALLIANCEBERNSTEIN L.P.9,557,149$294.4M
3Paradigm Biocapital Advisors LP7,967,836$213.8M
4ARROWSTREET CAPITAL, LIMITED PARTNERSHIP4,975,324$133.5M
5BlackRock, Inc.4,536,565$121.7M
6RENAISSANCE TECHNOLOGIES LLC4,414,550$118.4M
7Deep Track Capital, LP3,663,250$98.3M
8Harding Loevner LP3,231,601$86.7M
9DEERFIELD MANAGEMENT COMPANY, L.P.2,462,000$66.1M
10FIRST TRUST ADVISORS LP2,461,342$66.0M
11TWO SIGMA INVESTMENTS, LP2,339,432$62.8M
12MORGAN STANLEY2,184,701$58.6M
13FEDERATED HERMES, INC.1,251,590$33.6M
14FRANKLIN RESOURCES INC1,193,145$32.0M
15Pictet Asset Management Holding SA1,077,471$28.9M